Seattle City Guide

Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with GlaxoSmithKline

BOTHELL, Wash.–(BUSINESS WIRE)–Seattle Genetics, Inc. (NASDAQ:SGEN), announced today that it has entered into a collaboration agreement with GlaxoSmithKline (GSK) under which GSK will pay an upfront fee of $12 million for rights to utilize Seattle Genetics’ antibody-drug conjugate (ADC) technology with multiple antigens to be named by GSK. “By collaborating with leading companies such as GSK, we are broadening the reach of our proprietary ADC technology while also generating substa

Excerpt from:
Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with GlaxoSmithKline

Comments

Tell us what you're thinking...
and oh, if you want a pic to show with your comment, go get a gravatar!